Association of matrix metalloproteinase-12 polymorphisms with chronic obstructive pulmonary disease risk: A protocol for systematic review and meta analysis. Issue 31 (31st July 2020)

• Record Type: Journal Article
• Authors: Yang, Hongjing; Zhang, Chuantao; Wu, Jianying; Xiao, Wei; Xie, Xiaohong; Zeng, Zhu; Chen, Keling; Wang, Wujun; An, Xing; Tang, Wenjun; Huang, Qingsong
• Is Part Of: Medicine. Volume 99:Issue 31(2020)
• Publication Date: 2020-07-31
• Subjects: chronic obstructive pulmonary disease -- meta-analysis -- matrix metalloproteinase 12 -- polymorphism; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021543
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial disease with gene-environment interaction leading to airflow limitation through the respiratory tract. Reports on the association of matrix metalloproteinase 12 (MMP-12) polymorphisms with COPD have been controversial. A new systematic evaluation which could examine whether MMP-12 mutations are associated with the susceptibility to COPD is needed. Methods: We will search PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure and Google Scholar to obtain eligible case-control studies for meta-analysis. The time is limited from the construction of the library to July 2020. Two investigators systematically will extract relevant data within those included studies. The odds ratio and 95% confidence intervals will be used to assess the genetic association between the allelic, dominant and recessive models of MMP-12 gene polymorphisms and COPD risk. Stata 12.0 software and Revman 5.3 will be adopted for statistical analysis. This protocol reported under the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses Protocols statement. Results: This study will provide a better understanding of the association between MMP-12 polymorphisms and COPD risk. Conclusion: Publishing this protocol will minimise the possibility of bias due to post hoc changes to the analysis protocol.